<DOC>
	<DOCNO>NCT00088751</DOCNO>
	<brief_summary>Objectives . The propose clinical study two goal : First , assess efficacy central nervous system stimulant atypical antipsychotic treat behavioral symptom FTD second , characterize biological marker , include genetic , imaging , CSF proteins , FTD relation exist group Alzheimer 's patient . Rationale . Frontotemporal dementia ( FTD ) increasingly recognize important neuropsychiatric disorder . Symptoms FTD include disinhibition , impulsivity , apathy , affective lability , language dysfunction . The clinical syndrome associate frontal and/or anterior temporal atrophy image autopsy . Levels CSF proteins tau ( Beta ) -amyloid 1-42 , show diagnostic utility patient Alzheimer 's Disease ( AD ) , also find abnormal FTD . FTD less associate APOE genotype AD , however familial case FTD associate specific mutation gene encode tau protein . Currently , treatment prove effective alter course clinical symptom FTD . Design . Study subject include 50 male female patient mild-moderate frontotemporal dementia recruit participant NINDS protocol 02-N-0001 . In double-blinded crossover 11-week study without placebo control , patient treat stimulant ( dextroamphetamine ) atypical antipsychotic ( quetiapine ) . The primary outcome measure Neuropsychiatric Inventory Clinical Global Impression Change . Cerebrospinal fluid , cognitive genetic measure , brain MRIs , side effect scale also collect .</brief_summary>
	<brief_title>Treatment Study Frontotemporal Dementia</brief_title>
	<detailed_description>Objectives . The goal propose clinical study ass efficacy central nervous system stimulant atypical antipsychotic treat behavioral symptom FTD . Rationale . Frontotemporal dementia ( FTD ) increasingly recognize important neuropsychiatric disorder . Symptoms FTD include disinhibition , impulsivity , apathy , affective lability , language dysfunction . The clinical syndrome associate frontal and/or anterior temporal atrophy image autopsy . Currently , treatment prove effective alter course clinical symptom FTD . Design . Study subject include 20 male female patient mild-moderate frontotemporal dementia recruit participant NINDS protocols 02-N-0001 81-N-0010 . In double-blinded crossover 11-week study without placebo control , patient treat stimulant ( dextroamphetamine ) atypical antipsychotic ( quetiapine ) . The primary outcome measure Neuropsychiatric Inventory Clinical Global Impression Change . Cognitive measure side effect scale also collect .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . FTD diagnose LundManchester criterion include patient diagnose Semantic Dementia Primary Progressive Aphasia . 2 . Ages 45 95 year old . 3 . Mildtomoderate ( CDR 1 2 ) FTD assign durable power attorney . EXCLUSION CRITERIA : 1 . Diagnosis form dementia besides FTD , include AD , Lewy body dementia , vascular dementia , dementia associate Parkinson 's disease , Corticobasal Degeneration Progressive Supranuclear Palsy . 2 . Severe dementia ( CDR 3 ) . 3 . Known allergy serious adverse reaction quetiapine dextroamphetamine . 4 . Patient already receive stimulant ( methylphenidate , dextroamphetamine , pemoline , modafinil ) , antipsychotic medication , typical atypical , include prochlorperazine metoclopromide . 5 . Patients take following medication potential interaction dextroamphetamine : MAO use currently within 14 day prior start study , Furazolidone , Guanethidine , norepinephrine , sibutramine , tricyclic antidepressant , carbonic anhydrase inhibitor . 6 . Patients take following medication potential interaction quetiapine : Carbamazepine , clozapine , lithium , thioridazine . 7 . History CVA , significantly increase risk CVA ( e.g. , atrial fibrillation , recent TIA etc. ) . 8 . Symptomatic cardiovascular disease ( i.e. , angina , claudication , TIAs , syncope ) , uncontrolled hyper hypotension , tic disorder . 9 . Any medical contraindication performing procedure involve study include blood draw lumbar puncture . 10 . We require woman childbearing age pregnancy test prior start study medication use contraception course study . 11 . Patients previous negative trial stimulant . 12 . Patients history severe psychosis . 13 . Patients history recent substance abuse . 14 . Patients QTc prolongation baseline EKG . 15 . A score 2 less Communication Functional Ratings Swallowing Domain .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 1, 2009</verification_date>
	<keyword>Frontotemporal Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Atypical Antipsychotic</keyword>
	<keyword>Stimulant</keyword>
	<keyword>Apathy</keyword>
	<keyword>Disinhibition</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Dementia</keyword>
	<keyword>FTD</keyword>
</DOC>